Programmable Cell Therapy Platforms Market - Strategic Insights and Forecasts (2026-2031)

1. EXECUTIVE SUMMARY

2. MARKET SNAPSHOT

1. 2.1. Market Overview

2. 2.2. Market Definition

3. 2.3. Scope of the Study

4. 2.4. Market Segmentation

3. BUSINESS LANDSCAPE

1. 3.1. Market Drivers

2. 3.2. Market Restraints

3. 3.3. Market Opportunities

4. 3.4. Porter’s Five Forces Analysis

5. 3.5. Industry Value Chain Analysis

6. 3.6. Policies and Regulations

7. 3.7. Strategic Recommendations

4. TECHNOLOGICAL OUTLOOK

5. PROGRAMMABLE CELL THERAPY PLATFORMS MARKET BY PRODUCT

1. 5.1. Introduction

2. 5.2. Cell Therapy Platforms

3. 5.3. Gene Editing Tools & Platforms

4. 5.4. Vectors

5. 5.5. Reagents & Consumables

6. 5.6. Software & Digital Platforms

6. PROGRAMMABLE CELL THERAPY PLATFORMS MARKET BY TECHNOLOGY

1. 6.1. Introduction

2. 6.2. CRISPR gene editing

3. 6.3. TALENs (Transcription Activator-Like Effector Nucleases)

4. 6.4. Zinc Finger Nucleases (ZFNs)

5. 6.5. Synthetic Biology-Based Programming

6. 6.6. Viral Vector Engineering

7. 6.7. Non-Viral Gene Delivery Systems

7. PROGRAMMABLE CELL THERAPY PLATFORMS MARKET BY APPLICATION

1. 7.1. Introduction

2. 7.2. Oncology

3. 7.3. Genetic Disorders

4. 7.4. Autoimmune Diseases

5. 7.5. Neurological Disorders

6. 7.6. Cardiovascular Diseases

7. 7.7. Infectious Diseases

8. 7.8. Others

8. PROGRAMMABLE CELL THERAPY PLATFORMS MARKET BY GEOGRAPHY

1. 8.1. Introduction

2. 8.2. North America

   1. 8.2.1. USA

   2. 8.2.2. Canada

   3. 8.2.3. Mexico

3. 8.3. South America

   1. 8.3.1. Brazil

   2. 8.3.2. Argentina

   3. 8.3.3. Others

4. 8.4. Europe

   1. 8.4.1. United Kingdom

   2. 8.4.2. Germany

   3. 8.4.3. France

   4. 8.4.4. Spain

   5. 8.4.5. Others

5. 8.5. Middle East and Africa

   1. 8.5.1. Saudi Arabia

   2. 8.5.2. UAE

   3. 8.5.3. Others

6. 8.6. Asia Pacific

   1. 8.6.1. China

   2. 8.6.2. India

   3. 8.6.3. Japan

   4. 8.6.4. South Korea

   5. 8.6.5. Indonesia

   6. 8.6.6. Thailand

   7. 8.6.7. Others

9. COMPETITIVE ENVIRONMENT AND ANALYSIS

1. 9.1. Major Players and Strategy Analysis

2. 9.2. Market Share Analysis

3. 9.3. Mergers, Acquisitions, Agreements, and Collaborations

4. 9.4. Competitive Dashboard

10. COMPANY PROFILES

1. 10.1. Novartis AG

2. 10.2. Bristol-Myers Squibb

3. 10.3. Johnson & Johnson

4. 10.4. Sanofi

5. 10.5. Takeda Pharmaceutical Company

6. 10.6. Astellas Pharma

7. 10.7. Vertex Pharmaceuticals

8. 10.8. Sangamo Therapeutics

9. 10.9. Bluebird Bio

10. 10.10. Fate Therapeutics

11. 10.11. Allogene Therapeutics

11. APPENDIX

1. 11.1. Currency

2. 11.2. Assumptions

3. 11.3. Base and Forecast Years Timeline

4. 11.4. Key benefits for the stakeholders

5. 11.5. Research Methodology

6. 11.6. Abbreviations